Trial to Assess the Effectiveness of Educational Outreach in Prescription Guidelines
NCT01984034 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2014-11-07
Summary
Background: The Portuguese National Health Directorate has issued clinical practice guidelines on prescription of anti-inflammatory drugs and COX-2 inhibitors, acid suppressive therapy and proton pump inhibitors, and anti-platelets. However, their effectiveness in changing actual practice is unknown. The objectives will be to compare the effectiveness of educational outreach visits in the implementation of clinical guidelines in primary care in Portugal against usual implementation strategies and to conduct a cost-effectiveness analysis of this method.
Methods: The trial will be a parallel, cluster-randomized, unblinded, trial in primary care, with a 1:1 allocation ratio. This study will assess the effect of educational outreach visits on physician compliance with prescription guidelines. The general study hypothesis is whether educational outreach visits are superior to usual implementation of guidelines regarding the reduction of inappropriate prescribing (compliance with prescription guidelines). All National Health Service primary care units in the Lisbon (Portugal) region will be invited to participate. Units will be eligible if they are using an Electronic Health Record to issue prescriptions and have at least four doctors willing to participate. Doctors in intervention units will receive three educational outreach visits (one for each guideline) during a six months period, while the control group doctors will be offered an unrelated group training session (on using the international classification for primary care). Intervention visits will be one on one 15 minutes discussions conducted by guideline authors or trained family physicians at the physician's workplace. There are two primary outcomes, measured at the physician's level. One is the proportion of COX-2 inhibitors prescribed within the entire NSAID class, in defined daily doses 18 months after the intervention. The other is the proportion of omeprazole within the entire proton pump inhibitors class, in defined daily doses at 18 months post-intervention. Prescription data will be collected from the regional pharmacy claims database.
Conditions
- Inflammation
- Gastroesophageal Reflux
- Gastrointestinal Diseases
- Cardiovascular Diseases
Interventions
- BEHAVIORAL
-
Educational Outreach Visits
The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
- OTHER
-
Passive Dissemination
Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
Sponsors & Collaborators
-
Universidade Nova de Lisboa
lead OTHER
Principal Investigators
-
Pedro A. Caetano, PhD · Faculdade de Ciências Médicas - Universidade Nova de Lisboa (Nova Medical School)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 23 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-11-30
- Primary Completion
- 2014-06-30
- Completion
- 2015-12-31
Countries
- Portugal
Study Locations
More Related Trials
-
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
NCT01043185 ·Status: COMPLETED ·Phase: PHASE2
-
Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity
NCT00884247 ·Status: COMPLETED
-
Validation of RDQ Questionnaire
NCT00291746 ·Status: COMPLETED ·Phase: PHASE4
-
What is the Predictive Value of the Reflux Impact Scale
NCT00536328 ·Status: TERMINATED
-
Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
NCT03619811 ·Status: COMPLETED ·Phase: NA
-
Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment
NCT01103804 ·Status: COMPLETED
-
The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire
NCT00901004 ·Status: COMPLETED
-
Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ
NCT00914342 ·Status: COMPLETED
-
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
NCT01432392 ·Status: COMPLETED
-
An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease
NCT01134367 ·Status: COMPLETED
-
Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea
NCT01018160 ·Status: COMPLETED
-
Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.
NCT01601379 ·Status: COMPLETED
-
Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)
NCT00336219 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
NCT00842387 ·Status: COMPLETED
-
The Effect of PPI in Preventing Gastroesophageal Reflux Disease of Seafarers
NCT04696783 ·Status: UNKNOWN ·Phase: PHASE3
-
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
NCT00557401 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
NCT00163306 ·Status: COMPLETED ·Phase: PHASE3
-
Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational
NCT01378338 ·Status: COMPLETED
-
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
NCT00963144 ·Status: COMPLETED
-
Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response
NCT00392002 ·Status: COMPLETED ·Phase: PHASE4
-
AZD3355 Dose-escalation Study in Healthy Males
NCT00757419 ·Status: COMPLETED ·Phase: PHASE1
-
Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication
NCT02934152 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial
NCT01888549 ·Status: COMPLETED ·Phase: NA
-
Measurement of Gastric Secretion by MRI Under Inhibition by ProtonPump Inhibitors in Healthy Subjects & in GERD Patients
NCT01212614 ·Status: COMPLETED ·Phase: NA
-
A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece
NCT01215305 ·Status: COMPLETED